Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)

Yasutaka Takeda; Ichiro Sakuma; Shinya Hiramitsu; Mizuho Okada; Shinichiro Ueda; Masaru Sakurai

doi:10.3389/fcvm.2023.1172664

Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)

Front Cardiovasc Med. 2023 Mar 16:10:1172664. doi: 10.3389/fcvm.2023.1172664. eCollection 2023.

Authors

Yasutaka Takeda¹, Ichiro Sakuma², Shinya Hiramitsu³, Mizuho Okada⁴, Shinichiro Ueda⁵, Masaru Sakurai⁶

Affiliations

¹ Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
² Caress Sapporo Hokko Memorial Clinic, Sapporo, Japan.
³ Hiramitsu Heart Clinic, Nagoya, Japan.
⁴ Keiyukai Yoshida Hospital, Asahikawa, Japan.
⁵ Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan.
⁶ Department of Social and Environmental Medicine, Kanazawa Medical University, Uchinada, Japan.

Abstract

[This corrects the article DOI: 10.3389/fcvm.2023.1094100.].

Keywords: apolipoprotein B-48; atherosclerotic cardiovascular disease; hypertriglyceridemia; pemafibrate; polyunsaturated fatty acids; residual risk.

Publication types

Published Erratum